论文部分内容阅读
目的探讨多西他赛注射液及卡培他滨片与奥沙利铂注射液联合应用对食管癌患者术后化疗的效果。方法回顾性分析2010年6月至2012年12月我院行根治性手术治疗的101例食管癌患者的临床资料,其中男58例、女43例。根据治疗方法的不同将患者分为研究组(58例,男32例、女26例,术后接受多西他赛注射液及卡培他滨片与奥沙利铂注射液联合化疗)和对照组(43例,男26例、女17例,采取多西他赛注射液和卡培他滨片治疗,连续4个疗程),对比两组患者的化疗效果差异。结果化疗前,研究组和对照组患者的血清癌坯抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)、鳞状细胞癌抗原(SCC)的水平差异无统计学意义(P>0.05);化疗后,研究组患者的血清CEA、CA125、CA199、SCC的水平均显著低于对照组(P<0.05)。研究组患者1年生存率为92.59%、2年生存率70.37%,与对照组的86.49%、54.05%差异无统计学意义(P>0.05);但研究组3年生存率显著高于对照组(57.41%vs.32.43%,P<0.05)。研究组的平均生存时间长于对照组(31个月vs.22个月,P=0.001)。结论多西他赛注射液及卡培他滨片联合奥沙利铂注射液治疗食管癌术后患者能够显著降低患者血清肿瘤标记物的水平,对患者的远期生存有利,但应注意不良反应。
Objective To investigate the effect of docetaxel injection and capecitabine in combination with oxaliplatin injection on postoperative chemotherapy in patients with esophageal cancer. Methods The clinical data of 101 patients with esophageal cancer undergoing radical surgery in our hospital from June 2010 to December 2012 were retrospectively analyzed. There were 58 males and 43 females. According to the different treatment methods, the patients were divided into study group (58 cases, 32 males and 26 females, received docetaxel injection and capecitabine postoperatively combined with oxaliplatin injection) and control Group (43 cases, 26 males and 17 females, taking docetaxel injection and capecitabine tablets for 4 consecutive courses of treatment), the difference between the two groups was compared. Results Before chemotherapy, the levels of CEA, CA125, CA199 and SCC in study group and control group had no significant difference (P> 0.05). After chemotherapy, the levels of serum CEA, CA125, CA199 and SCC in the study group were significantly lower than those in the control group (P <0.05). The 1-year survival rate was 92.59% in the study group and 70.37% in 2-year survival rate, which was not significantly different from 86.49% and 54.05% in the control group (P> 0.05). However, the 3-year survival rate in the study group was significantly higher than that in the control group (57.41% vs.32.43%, P <0.05). The mean survival time of study group was longer than that of control group (31 months vs.22 months, P = 0.001). Conclusion Docetaxel and capecitabine combined with oxaliplatin in the treatment of postoperative esophageal cancer patients can significantly reduce the level of serum tumor markers in patients with long-term survival benefit, but should pay attention to adverse reactions .